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Method: This is a retrospective study, in which all interventions documented by pharmacists in the hospital, from January 2005 to December 2014 were included for analysis. The interventions documented were examined to identify types of MRPs, common medications involved, and the risks of potential impact of interventions were assessed.
Results: There were a total of 1544 interventions documented. The five main intervention types were 1) dose/frequency/ time incorrect (47.67%, n = 736); 2) prescribing clarification (16.9%, n = 261); 3) hospital protocol (10.69%, n = 165); 4) medicines omissions (7.71%, n = 119); and 5) therapeutic monitoring (4.92%, n = 76). Parenteral nutrition (30.3%), gentamicin (11.6%), caffeine (9.0%), and iron (6.0%) were the most common medications involved. The documented intervention rate was 1 intervention per 100 medication charts reviewed. An average of 26.75% of the interventions was regarded as high risk and 2.14% as extreme risk. The medications involved in high and extreme risk MRPs include gentamicin, caffeine and beta-lactam antibiotics.
Conclusions: Our study demonstrates that hospital pharmacists contribute to the prevention of MRPs in the neonatology patients. This study also highlighted several targeted areas for future staff education to address the MRPs identified for effective, safe and efficient drug therapy. Background: Resuscitation with intact placental circulation (RIPC) seems crucial in babies requiring resuscitation. This allows continued oxygen supply from placenta. Devices developed for RIPC are scarce. Developing a compact platform that can move near mothers without compromising space and resources for delivery room personnel is a challenge.
AN INNOVATIVE WARMER-CRADLE FOR NEONATAL RESUSCITATION WITH INTACT PLACENTAL CIRCULATION
Methods: The multidisciplinary product development team consisted of Neonatologists, Obstetricians, Engineers and industrial Designers. Radiant heat source was predefined mandatory. Three-dimensional conceptual sketch diagram with accurate measurements and placements of components was conceived. Functional and safety aspects of components were reviewed and serial prototypes with appropriate modifications were designed to achieve a satisfactory final product. We evaluated the final product in simulated manikin resuscitations across various settings. We named it ICAN RIPC Warmer-cradle.
Results: Our device features an overhead radiant source (160x80x60 cm) with 180o rotatability facilitating approach from any side. Cradle is height adjustable and has unique rotating and sliding-out features enabling reach within 50 cm of mother's perineum. Base is short (80x60 cm) with easy mobility permitting close positioning. The device accommodates add-ons like T-piece resuscitator, oxygen blender, suction apparatus and APGAR timer in a modular design.
Conclusion: ICAN RIPC warmer-cradle is an innovative and ergonomic resuscitation unit, designed specifically to facilitate resuscitation with intact placental circulation across different delivery settings. It appears suitable for in-house neonatal transport too. Efficacy and safety are established in simulation models and 20 uncomplicated deliveries in various settings. A service evaluation study is underway to determine feasibility and safety of this device in actual clinical situations.
DEVELOPING A HUMAN MILK BASED HUMAN MILK FORTIFIER USING NOVEL METHODS -A FEASIBILITY STUDY
Sivam Thanigainathan 1* , Sundaram produce dry human milk powder. Fixed volumes of different milk samples were tested (five repeats to assess consistency). Centrifugation (6000 rpm) separated fat. Remaining skimmed milk was run through ultrafiltration (100 GPD, 150 minutes) to isolate protein from lactose. Nutritional content, solubility, osmolality on reconstitution, stability over time and costs incurred were analysed. Results: Each gram of HHMF(Spray-dried) yielded 3.9 Calorie, 0.12grams protein, 0.13grams fat and 0.39grams lactose against HHMF(lyophilized) attaining 3.8 Calorie, 0.12grams protein, 0.12grams fat and 0.39grams lactose. Moisture content was 4.12grams vs 3.72grams/100 g and solubility index was 99.75% vs 99.9%. Both powders retained the nutritional content after one month storage at room temperature. Centrifuged cream provided 7.7 grams/dl of fat. Ultrafiltration of skimmed milk increased the protein concentration from 1.3 grams/dl to 3.1 grams/dl retaining lactose at 7.3 grams/dl.
Conclusion: Lyophilisation and spray drying are potential strategies to develop dry HHMF in a consistent manner. These
